Nick zheng (@pick1998_2) profile picture

Biotech stock trading and investing for 35 years. PhD in biology, MS in computer science.

Las Vegas
Joined November 2011
Photo by Nick zheng (@pick1998_2)Photo by Nick zheng (@pick1998_2)Photo by Nick zheng (@pick1998_2)Photo by Nick zheng (@pick1998_2)Photo by Nick zheng (@pick1998_2)Photo by Nick zheng (@pick1998_2)Photo by Nick zheng (@pick1998_2)Photo by Nick zheng (@pick1998_2)Photo by Nick zheng (@pick1998_2)Photo by Nick zheng (@pick1998_2)
$HELP produced very good data on efficacy in 1st pIII trial as adjunctive (add-on) therapy for MDD, even similar to placebo-adjusted effect by $DFTX as monotherapy), which is more impressive. HLP003 is deuterated psilocin, it should change chemistry of psilocin. Better than $CMPS
1
2
12
2,318
$HELP correction: HLP003 is deuterated psilocin, it should NOT change chemistry of psilocin. Better than $CMPS
1
4
647
$PEPG added at 4.5, averaging down to 4.95. Will add more at 4. Surely, the lower, the better.
2
11
2,597
$LQDA $PGEN when a biotech company makes a superior product, no worry about your market. Those of inferior products often expands the total market with their marketing cost to help you accelerate revenue growth.
2
22
2,641
$NVDA CEO Jansen Huang got ousted for his affair with a lady, wiping out hundreds of billions of market value. What could be sadder than this for a successful American company? It proved traditional Chinese wisdom again: For a man, nothing is more risky than a lady.
1
8
1,044
$LQDA 50s again, amazing recovery from recent low at 20s. Buy when market is at panic when the company has a good product. $PGEN will recover to new highs, too.
1
10
1,409
$SVRA is moving up to PDUFA next Fri, but still at 5.
3
1,054
$PEPG will good data (~50% splicing, acceptable safety) from high dose cohort (12.5mg/kg) in 1H27 and 1 year follow-up from lower dose qualify NDA for accelerated approval? if yes, this stock is way too cheap under $1B valuation right now.
1
7
1,369
$PEPG initiated a long pos at 5.5. 46% splicing correction for DM1 is so good. It's pII trial at dose of 10mg/kg. high dose 12.5mg/kg data 1H27. From pI single dose study, 15mg/kg achieved 53.7% mean splicing. So I expect 12.5mg/kg dose should give around 50% splicing. Strong Buy
2
1
24
2,816
$REPL $PGEN my top pos. Crazy movement in price. Just two months ago, $PGEN is a big winner; now it has given back almost all gain; while $REPL has surged to my #1 position. To balance portfolio, I am selling some $REPL and buy more $PGEN. Both have best products for unmet needs
3
15
1,804
$INO $70m offering at 1.05 before discount, ripping off shareholders again, esp. naive new retail investors who bought it on FDA approval. i only see it will bleed faster and dilute more before seeing any revenue. this 70m will be gone even the confirmatory trial starts.
6
3
15
3,374
$XBI down 5%, and $PGEN, a profitable biotech stock, down another 20%. What a disaster day :-) But I hold all my bio stocks that are at commercial stage or near FDA approval such as $LRMR $SVRA $QURE
2
1
17
2,352
CITIZENS $PGEN Weakness following competitor approval is stark overreaction and presents compelling opportunity to buy $PGEN PAPZIMEOS complete response rate of 51% compared to 27% complete response rate achieved with VOCERYQ $INO PAPZIMEOS label also #broader than VOCERYQ
7
2
22
5,420
$CNTB does it and its Chinese partner Simere Pharm have a better version of Dupixent? Simere submitted NDA for atopic dermatitis in China (approval by April 2027). Dupixent sales total 5.7B euro 3Q26: bloomberg.com/news/articles/…
1
2
1,568
Why $CNTB stock price stays under 1? Please share some of your insights please.
1
705
Replying to @jy201506
Thanks for sharing, so basically $IOVA is competing with $REPL now in refractory melanoma, and $REPL has a an easier to provide and widely anticipated therapy at $1.4b enterprise value and $IOVA has a $3.7b enterprise value with all the additional hassle. got it
1
1
4
834
$IOVA revenue forecast:
1
1
9
1,962
$IOVA to reload it at single digit sounds like a dream just a few days ago :-) Is the company worth $4B? I bet.
11
1,484
$IOVA market may be overacting. A BLA in 2027 for advanced NSCLC is still possible as last resort for pts who have exhausted other options. The enrichment plan is for the future (5 yrs later?). But do not forget: $IOVA is making $500M revenue from melanoma treatment. Reload it.
3
1
20
2,766
$IOVA back to single digit (down 36% to 9.4). Waiting to reload it. (I sold too earlier before it jumped on revenue bumping up). Good big view: The only TIL therapy with increasing revenue (next year should be over 500M). Bad view: expanding from melanoma to NSCLC may take longer
1
10
1,746